This company will make money from Moderna's COVID-19 vaccine even if Moderna doesn't.
News & Analysis: Catalent
The contract manufacturer will be able to supply hundreds of millions of doses of AZD1222 starting in August.
A combination of acquisitions and coronavirus vaccine manufacturing deals have pushed shares to an all-time high, but not all earnings are flowing to common stockholders.
The big pharma giant will outsource the production of medicines it sells now for a chance to halt the virus responsible for COVID-19 in its tracks.
It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.
CTLT earnings call for the period ending March 31, 2020.
Catalent expects to be ready to manufacture the drug giant's lead COVID-19 vaccine by January.
The drug manufacturer is doubling down on biologic drugs to grow profits, but not all of the additional earnings will trickle down the income statement for individual investors.
CTLT earnings call for the period ending December 31, 2019.
Drug manufacturer Catalent is ready to capitalize on the drug industry's shifting norms.